HeartBeat.bio AG

HeartBeat.bio is a 2021 founded drug discovery company focusing on the development of a high-throughput 3D screening platform tackeling cardiomyopathies, cardiotoxicity and heart failure. Our core technology is based on the world-wide first, self-organizing cardiac organoids (cardioids) which resemble the human physiology of a human heart chamber in a way that allows for the cost-efficient and large scale in-vitro analysis of crucial clinical parameters associated with various cardiac diseases. The cardioid-based screening platform has the potential to radically change the current cardiovascular drug discovery paradigm.